Hong Kong seeks to cash in on frenzy for Chinese biotech stocks
HK bourse is in the midst of weighing a proposal that would allow biotech firms to list before they turn a profit
Hong Kong
CHINESE drug companies have been on a tear in the US stock market. Now, entrepreneurs and investors betting on the Asian country's fledgling biotechnology industry see another reason for optimism.
The stock exchange in Hong Kong - home to the world's fourth-largest equity market - is in the midst of weighing a proposal that would allow biotech companies to list even before they turn a profit.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action